A dynamic population model of disease progression in COPD

M. Hoogendoorn, M. P M H Rutten-van Mölken, R. T. Hoogenveen, M. L L van Genugten, A (Sonia) Buist, E. F M Wouters, T. L. Feenstra

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

To contribute to evidence-based policy making, a dynamic Dutch population model of chronic obstructive pulmonary disease (COPD) progression was developed. The model projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025, taking into account population dynamics and changes in smoking prevalence over time. It was estimated that of all diagnosed COPD patients in 2000, 27% had mild, 55% moderate, 15% severe and 3% very severe COPD. The severity distribution of COPD incidence was computed to be 40% mild, 55% moderate, 4% severe and 0.1% very severe COPD. Disease progression was modelled as decline in forced expiratory voume in one second (FEV1) % predicted depending on sex, age, smoking and FEV1 % pred. The relative mortality risk of a 10-unit decrease in FEV1 % pred was estimated at 1.2. Projections of current practice were compared with projections assuming that each year 25% of all COPD patients receive either minimal smoking cessation counselling or intensive counselling plus bupropion. In the projections of current practice, prevalence rates between 2000-2025 changed from 5.1 to 11 per 1,000 inhabitants for mild, 11 to 14 per 1,000 for moderate, 3.0 to 3.9 per 1,000 for severe and from 0.5 to 1.3 per 1,000 for very severe COPD. Costs per inhabitant increased from €1.40 to 3.10 for mild, €6.50 to 9.00 for moderate, €6.20 to 8.50 for severe and from €3.40 to 9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were cost-effective with minimal counselling generating net savings. In conclusion, the chronic obstructive pulmonary disease progression model is a useful instrument to give detailed information about the future burden of chronic obstructive pulmonary disease and to assess the long-term impact of interventions on this burden. Copyright

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalEuropean Respiratory Journal
Volume26
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Population Dynamics
Chronic Obstructive Pulmonary Disease
Disease Progression
Counseling
Smoking Cessation
Costs and Cost Analysis
Smoking
Bupropion
Mortality
Policy Making
Incidence

Keywords

  • Chronic obstructive pulmonary disease
  • Cost-effectiveness
  • Disease severity
  • Epidemiology
  • Model
  • Smoking cessation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hoogendoorn, M., Rutten-van Mölken, M. P. M. H., Hoogenveen, R. T., van Genugten, M. L. L., Buist, A. S., Wouters, E. F. M., & Feenstra, T. L. (2005). A dynamic population model of disease progression in COPD. European Respiratory Journal, 26(2), 223-233. https://doi.org/10.1183/09031936.05.00122004

A dynamic population model of disease progression in COPD. / Hoogendoorn, M.; Rutten-van Mölken, M. P M H; Hoogenveen, R. T.; van Genugten, M. L L; Buist, A (Sonia); Wouters, E. F M; Feenstra, T. L.

In: European Respiratory Journal, Vol. 26, No. 2, 08.2005, p. 223-233.

Research output: Contribution to journalArticle

Hoogendoorn, M, Rutten-van Mölken, MPMH, Hoogenveen, RT, van Genugten, MLL, Buist, AS, Wouters, EFM & Feenstra, TL 2005, 'A dynamic population model of disease progression in COPD', European Respiratory Journal, vol. 26, no. 2, pp. 223-233. https://doi.org/10.1183/09031936.05.00122004
Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, van Genugten MLL, Buist AS, Wouters EFM et al. A dynamic population model of disease progression in COPD. European Respiratory Journal. 2005 Aug;26(2):223-233. https://doi.org/10.1183/09031936.05.00122004
Hoogendoorn, M. ; Rutten-van Mölken, M. P M H ; Hoogenveen, R. T. ; van Genugten, M. L L ; Buist, A (Sonia) ; Wouters, E. F M ; Feenstra, T. L. / A dynamic population model of disease progression in COPD. In: European Respiratory Journal. 2005 ; Vol. 26, No. 2. pp. 223-233.
@article{fbb27b73a70d41e6955df452bb114c11,
title = "A dynamic population model of disease progression in COPD",
abstract = "To contribute to evidence-based policy making, a dynamic Dutch population model of chronic obstructive pulmonary disease (COPD) progression was developed. The model projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025, taking into account population dynamics and changes in smoking prevalence over time. It was estimated that of all diagnosed COPD patients in 2000, 27{\%} had mild, 55{\%} moderate, 15{\%} severe and 3{\%} very severe COPD. The severity distribution of COPD incidence was computed to be 40{\%} mild, 55{\%} moderate, 4{\%} severe and 0.1{\%} very severe COPD. Disease progression was modelled as decline in forced expiratory voume in one second (FEV1) {\%} predicted depending on sex, age, smoking and FEV1 {\%} pred. The relative mortality risk of a 10-unit decrease in FEV1 {\%} pred was estimated at 1.2. Projections of current practice were compared with projections assuming that each year 25{\%} of all COPD patients receive either minimal smoking cessation counselling or intensive counselling plus bupropion. In the projections of current practice, prevalence rates between 2000-2025 changed from 5.1 to 11 per 1,000 inhabitants for mild, 11 to 14 per 1,000 for moderate, 3.0 to 3.9 per 1,000 for severe and from 0.5 to 1.3 per 1,000 for very severe COPD. Costs per inhabitant increased from €1.40 to 3.10 for mild, €6.50 to 9.00 for moderate, €6.20 to 8.50 for severe and from €3.40 to 9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were cost-effective with minimal counselling generating net savings. In conclusion, the chronic obstructive pulmonary disease progression model is a useful instrument to give detailed information about the future burden of chronic obstructive pulmonary disease and to assess the long-term impact of interventions on this burden. Copyright",
keywords = "Chronic obstructive pulmonary disease, Cost-effectiveness, Disease severity, Epidemiology, Model, Smoking cessation",
author = "M. Hoogendoorn and {Rutten-van M{\"o}lken}, {M. P M H} and Hoogenveen, {R. T.} and {van Genugten}, {M. L L} and Buist, {A (Sonia)} and Wouters, {E. F M} and Feenstra, {T. L.}",
year = "2005",
month = "8",
doi = "10.1183/09031936.05.00122004",
language = "English (US)",
volume = "26",
pages = "223--233",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - A dynamic population model of disease progression in COPD

AU - Hoogendoorn, M.

AU - Rutten-van Mölken, M. P M H

AU - Hoogenveen, R. T.

AU - van Genugten, M. L L

AU - Buist, A (Sonia)

AU - Wouters, E. F M

AU - Feenstra, T. L.

PY - 2005/8

Y1 - 2005/8

N2 - To contribute to evidence-based policy making, a dynamic Dutch population model of chronic obstructive pulmonary disease (COPD) progression was developed. The model projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025, taking into account population dynamics and changes in smoking prevalence over time. It was estimated that of all diagnosed COPD patients in 2000, 27% had mild, 55% moderate, 15% severe and 3% very severe COPD. The severity distribution of COPD incidence was computed to be 40% mild, 55% moderate, 4% severe and 0.1% very severe COPD. Disease progression was modelled as decline in forced expiratory voume in one second (FEV1) % predicted depending on sex, age, smoking and FEV1 % pred. The relative mortality risk of a 10-unit decrease in FEV1 % pred was estimated at 1.2. Projections of current practice were compared with projections assuming that each year 25% of all COPD patients receive either minimal smoking cessation counselling or intensive counselling plus bupropion. In the projections of current practice, prevalence rates between 2000-2025 changed from 5.1 to 11 per 1,000 inhabitants for mild, 11 to 14 per 1,000 for moderate, 3.0 to 3.9 per 1,000 for severe and from 0.5 to 1.3 per 1,000 for very severe COPD. Costs per inhabitant increased from €1.40 to 3.10 for mild, €6.50 to 9.00 for moderate, €6.20 to 8.50 for severe and from €3.40 to 9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were cost-effective with minimal counselling generating net savings. In conclusion, the chronic obstructive pulmonary disease progression model is a useful instrument to give detailed information about the future burden of chronic obstructive pulmonary disease and to assess the long-term impact of interventions on this burden. Copyright

AB - To contribute to evidence-based policy making, a dynamic Dutch population model of chronic obstructive pulmonary disease (COPD) progression was developed. The model projects incidence, prevalence, mortality, progression and costs of diagnosed COPD by the Global Initiative for Chronic Obstructive Lung Disease-severity stage for 2000-2025, taking into account population dynamics and changes in smoking prevalence over time. It was estimated that of all diagnosed COPD patients in 2000, 27% had mild, 55% moderate, 15% severe and 3% very severe COPD. The severity distribution of COPD incidence was computed to be 40% mild, 55% moderate, 4% severe and 0.1% very severe COPD. Disease progression was modelled as decline in forced expiratory voume in one second (FEV1) % predicted depending on sex, age, smoking and FEV1 % pred. The relative mortality risk of a 10-unit decrease in FEV1 % pred was estimated at 1.2. Projections of current practice were compared with projections assuming that each year 25% of all COPD patients receive either minimal smoking cessation counselling or intensive counselling plus bupropion. In the projections of current practice, prevalence rates between 2000-2025 changed from 5.1 to 11 per 1,000 inhabitants for mild, 11 to 14 per 1,000 for moderate, 3.0 to 3.9 per 1,000 for severe and from 0.5 to 1.3 per 1,000 for very severe COPD. Costs per inhabitant increased from €1.40 to 3.10 for mild, €6.50 to 9.00 for moderate, €6.20 to 8.50 for severe and from €3.40 to 9.40 for very severe COPD (price level 2000). Both smoking cessation scenarios were cost-effective with minimal counselling generating net savings. In conclusion, the chronic obstructive pulmonary disease progression model is a useful instrument to give detailed information about the future burden of chronic obstructive pulmonary disease and to assess the long-term impact of interventions on this burden. Copyright

KW - Chronic obstructive pulmonary disease

KW - Cost-effectiveness

KW - Disease severity

KW - Epidemiology

KW - Model

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=23144437068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23144437068&partnerID=8YFLogxK

U2 - 10.1183/09031936.05.00122004

DO - 10.1183/09031936.05.00122004

M3 - Article

C2 - 16055869

AN - SCOPUS:23144437068

VL - 26

SP - 223

EP - 233

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 2

ER -